超快速乳腺 MRI 预测新辅助治疗后病理反应的前瞻性评估

Background Ultrafast dynamic contrast-enhanced (DCE) MRI parameters are associated with breast cancer aggressiveness.

However, the role of these parameters as predictive biomarkers for pathologic response after neoadjuvant chemotherapy (NAC) has been poorly investigated. Purpose To assess whether semiquantitative perfusion parameters calculated at initial ultrafast DCE MRI are associated with early prediction for pathologic response after NAC in participants with breast cancer. Materials and Methods This prospective single-center study included consecutive women with nonmetastatic invasive breast cancer treated with NAC followed by surgery who underwent initial ultrafast DCE MRI between December 2020 and August 2021. Six semiquantitative ultrafast DCE MRI parameters were calculated for each participant from the fitted time-signal intensity curve. Multivariable logistic regression was used to identify independent predictors of pathologic complete response (pCR) and residual cancer burden (RCB). Results Fifty women (mean age, 49 years ± 12 [SD]) were included in the study; 20 achieved pCR and 25 achieved low RCB (RCB-0 and I). A wash-in slope (WIS) cutoff value of 1. 6% per second had a sensitivity of 94% (17 of 18 participants) and a specificity of 59% (19 of 32 participants) for pCR. A WIS of more than 1. 6% per second (odds ratio [OR], 8. 4 [95% CI: 1.

5, 48. 2]; P = . 02), human epidermal growth factor receptor 2 (HER2) positivity (OR, 6. 3 [95% CI: 1. 5, 27. 4]; P = . 01), and tumor-infiltrating lymphocytes of more than 10% (OR, 6. 9 [95% CI: 1. 3, 37. 7]; P = . 03) were independent predictive factors of pCR. The area under the receiver operating characteristic curve of the three-component model, which included WIS, tumor-infiltrating lymphocytes, and HER2 positivity, was 0. 92 (95% CI: 0. 84, 0. 99). A WIS of more than 1. 6% per second was associated with higher pCR rates in the HER2-positive (OR, 21. 7 [95% CI: 1. 8, 260. 6]; P = . 02) breast cancer subgroup.

For luminal HER2-negative and triple-negative breast cancers, a WIS of more than 1. 6% per second was associated with low RCB (OR, 11. 0 [95% CI: 1. 1, 106. 4]; P = . 04). Conclusion The wash-in slope (WIS) assessment at initial ultrafast dynamic contrast-enhanced MRI may be used to predict pathologic complete response (pCR) in participants with breast cancer.

The WIS value was used to identify two subsets of human epidermal growth factor receptor 2-positive cancers with distinct pCR rates. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Lee and Moy in this issue.